Title:
ブスピロンの局所製剤および使用
Document Type and Number:
Japanese Patent JP2006521339
Kind Code:
A
Abstract:
A liquid or semi-solid topical formulation of buspirone, when applied to human epidermis in vitro (following methods defined herein), results in a transepidermal flux rate of buspirone (individual or mean data) in one or more of the following ranges: 0.1 to 1.1 mug/cm2/hour as assessed over 5 hours following application; 0.09 to 0.60 mug/cm2/hour as assessed over 13 hours following application; 0.09 to 0.48 mug/cm2/hour as assessed over 24 hours following application; 0.08 to 0.46 mug/cm2/hour as assessed over 30 hours following application; and 0.08 to 0.39 mug/cm2/hour as assessed over 48 hours following application. Buspirone is useful for the manufacture of a topical medicament for use in the treatment of pruritus or an immune-related skin disease.
More Like This:
| JP2022552735 | GLP-1R modulating compounds |
| JP2023011846 | COMPOSITIONS AND METHODS FOR TREATMENT OF FUNGAL INFECTIONS |
| JP2020507588 | Piperidine Substitution MnK Inhibitors and Related Methods |
Inventors:
David Kabbalah
Robert William Gristwood
Robert William Gristwood
Application Number:
JP2006505999A
Publication Date:
September 21, 2006
Filing Date:
March 22, 2004
Export Citation:
Assignee:
Arachnova Therapeutics Ltd.
International Classes:
A61K31/506; A61K9/00; A61K9/06; A61K9/107; A61K47/00; A61P1/16; A61P7/08; A61P13/12; A61P17/00; A61P17/02; A61P17/04; A61P17/06; A61P17/16; A61P35/00; A61P37/00; A61P37/08; C07D401/12
Attorney, Agent or Firm:
Aoyama Aoi
Mitsutaka Iwasaki
Shoji Nakajima
Mitsutaka Iwasaki
Shoji Nakajima